Publications by authors named "Eugene Sun"

Claim this Profile
C
Corrigendum to "Candidate anti-tuberculosis medicines and regimens under clinical evaluation" [Clin Microbiol Infect 30(9) (2024) 1131-1138].
Michael Hoelscher, David Barros-Aguirre, Masoud Dara, Norbert Heinrich, Eugene Sun

Clin Microbiol Infect· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond.
Saskia Janssen, Caryn Upton, Veronique R de Jager, Christo van Niekerk, Rodney Dawson, Eugene Sun

Am J Respir Crit Care Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants.
Antonio Lombardi, Fran Pappas, Paul Bruinenberg, Jerry Nedelman, Rajneesh Taneja, Eugene Sun

Antimicrob Agents Chemother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictable excess hepatotoxicity in the SimpliciTB trial - Authors' reply.
Muge Cevik, Maria Beumont, Eugene Sun, Derek J Sloan, Stephen H Gillespie

Lancet Infect Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects.
Antonio Lombardi, Fran Pappas, Jerry Nedelman, Dean Hickman, Sarah Jaw-Tsai, Eugene Sun

Antimicrob Agents Chemother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Muge Cevik, Lindsay C Thompson, Caryn Upton, Valéria Cavalcanti Rolla, Mookho Malahleha, Eugene Sun

Lancet Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Candidate anti-tuberculosis medicines and regimens under clinical evaluation.
Michael Hoelscher, David Barros-Aguirre, Masoud Dara, Norbert Heinrich, Eugene Sun

Clin Microbiol Infect· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target regimen profiles for tuberculosis treatment.
Christian Lienhardt, Kelly E Dooley, Payam Nahid, Charles Wells, Theresa S Ryckman, Eugene Sun

Bull World Health Organ· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A Witney, Eugene Sun

PLOS Glob Public Health· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regimens for Drug-Resistant Tuberculosis. Reply.
Juliano Timm, Angela M Crook, Eugene Sun

N Engl J Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Francesca Conradie, Tatevik R Bagdasaryan, Sergey Borisov, Pauline Howell, Lali Mikiashvili, Eugene Sun

N Engl J Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
Anna Bateson, Julio Ortiz Canseco, Timothy D McHugh, Adam A Witney, Silke Feuerriegel, Eugene Sun

J Antimicrob Chemother· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging longitudinal clinical laboratory results to improve prenatal care.
Richard VanNess, Kathleen M Swanson, David G Grenache, Mark Koenig, Lauretta Dozier, Eugene Sun

Am J Manag Care· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.
Jeffrey S Litwin, Michael S Benedict, Michael D Thorn, Laura E Lawrence, Sue K Cammarata, Eugene Sun

Antimicrob Agents Chemother· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
Randall Hoover, Thomas Hunt, Michael Benedict, Susan K Paulson, Laura Lawrence, Eugene Sun

Clin Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Randall Hoover, Thomas Hunt, Michael Benedict, Susan K Paulson, Laura Lawrence, Eugene Sun

Clin Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community health workers and medicaid managed care in New Mexico.
Diane Johnson, Patricia Saavedra, Eugene Sun, Ann Stageman, Dodie Grovet

J Community Health· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with risk of surgical wound infections.
Christopher S Hollenbeak, Judith R Lave, Timothy Zeddies, Yanfen Pei, Constance E Roland, Eugene F Sun

Am J Med Qual· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.
Kit N Simpson, Michelle P Luo, Elinor Chumney, Eugene Sun, Scott Brun

HIV Clin Trials· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
Gondi N Kumar, Venkata K Jayanti, Marianne K Johnson, John Uchic, Samuel Thomas, Eugene Sun

Pharm Res· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Martin S King, Barry M Bernstein, Sharon L Walmsley, Renslow Sherer, Judith Feinberg, Eugene Sun

J Infect Dis· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Dale J Kempf, Martin S King, Barry Bernstein, Paul Cernohous, Eric Bauer, Eugene Sun

J Infect Dis· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
Joseph J Eron, Judith Feinberg, Harold A Kessler, Harold W Horowitz, Mallory D Witt, Eugene Sun

J Infect Dis· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
Hongmei Mo, Liangjun Lu, Tatyana Dekhtyar, Kent D Stewart, Eugene Sun

Antiviral Res· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
Martin Markowitz, Michael Louie, Arlene Hurley, Eugene Sun, Michele Di Mascio

J Virol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis